Mohammad Haghighi

Mohammad Haghighi

Auto-generated profile, based on publicly available information

Mohammad Haghighi

Research Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, Iran

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
HAHamid Afshar
Hamid Afshar
HRHamidreza Roohafza
Hamidreza Roohafza
HMHamid Mohammad-Beigi
Hamid Mohammad-Beigi
MHMohammad Haghighi
Mohammad Haghighi
LJLeila Jahangard
Leila Jahangard
HHHasan Hafezian
Hasan Hafezian
This study aimed to evaluate the efficacy and safety of N-acetylcysteine, a glutamate-modulating agent, in patients with treatment-refractory obsessive-compulsive disorder as an adjunct to serotonin reuptake inhibitor treatment. Forty-eight patients (36 women; mean ± SD age, 30.93 ± 4.99) with obsessive-compulsive disorder who failed to respond to a course of serotonin reuptake inhibitor treatment were randomized to a 12-week intervention period of N-acetylcysteine (up to 2400 mg/d) or placebo. Primary outcome measures were the change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score from baseline to end point and the rate of full response in each group at the end of trial. Full response was defined as 35% or greater reduction in Y-BOCS score from baseline. Changes of Y-BOCS score were different over time (P < 0.001) and between groups (P < 0.001). N-acetylcysteine-assigned patients showed significantly improved mean Y-BOCS score (P = 0.003) and Clinical Global Impression-Severity of Illness scale score (P = 0.01) but not Clinical Global Impression-Improvement scale score at study end point. Of the patients in the N-acetylcysteine group, 52.6% were full responders at the end of the study, which was significantly higher than 15% of the patients in the placebo group (P = 0.013). This trial suggests that N-acetylcysteine may be a safe and effective option to augment standard treatment in patients with refractory obsessive-compulsive disorder.

23 March 2013 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MHMohammad Haghighi
Mohammad Haghighi
LJLeila Jahangard
Leila Jahangard
HMHamid Mohammad-Beigi
Hamid Mohammad-Beigi
HBHafez Bajoghli
Hafez Bajoghli
HHHassan Hafezian
Hassan Hafezian
Serge BrandSerge Brand
Serge Brand

4 October 2016 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
AGA. Ghajar
A. Ghajar
SNS. M. Neishabouri
S. M. Neishabouri
NVN. Velayati
N. Velayati
LJL. Jahangard
L. Jahangard
NMNasrin Matinnia
Nasrin Matinnia
SAS. Akhondzadeh
S. Akhondzadeh
Introduction: Saffron (Crocus sativus L.) has demonstrated antidepressant effects in clinical studies and extensive anxiolytic effects in experimental animal models. Methods: 66 patients with major depressive disorder accompanied by anxious distress were randomly assigned to receive either saffron (30 mg/day) or citalopram (40 mg/day) for 6 weeks. Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) were used to assess treatment effect during the trial. Results: 60 participants finished the study. Patients who received either saffron or citalopram showed significant improvement in scores of the Hamilton Rating Scale for Depression (P-value<0.001 in both groups) and Hamilton Rating Scale for Anxiety (P-value<0.001 in both groups). Comparison of score changes between the 2 trial arms showed no significant difference (P-value=0.984). Frequency of side effects was not significantly different between the 2 groups. Discussion: The present study indicates saffron as a potential efficacious and tolerable treatment for major depressive disorder with anxious distress. * The first three authors contributed equally in this study.

27 June 2014 in Neuropsychobiology
Verified
Journal Article
Closed access
PDF file
MAMohammad Ahmadpanah
Mohammad Ahmadpanah
PSParasto Sabzeiee
Parasto Sabzeiee
SHSeyed Mohammad Hosseini
Seyed Mohammad Hosseini
STSaadat Torabian
Saadat Torabian
MHMohammad Haghighi
Mohammad Haghighi
Serge BrandSerge Brand
Serge Brand
Objectives: In light of the high prevalence of sleep disorders in patients suffering from posttraumatic stress disorder (PTSD), this study sought to compare the effect of prazosin and hydroxyzine on sleep quality in this patient group. Methods: A total of 100 patients suffering from PTSD were assessed (mean age = 35.51 years, SD = 6.41; 28% females). Next, they were randomly assigned to one of three treatment groups: prazosin (33 patients), hydroxyzine (34 patients) or placebo (33 patients). The trial lasted for 8 weeks. The patients' sleep quality was assessed using the Pittsburgh Sleep Quality Index. Items taken from the Mini International Neuropsychiatric Interview were used to operationalize PTSD. Results: Compared to controls, patients treated with prazosin and hydroxyzine reported improved sleep and less nightmares. Improvement was greatest in patients treated with prazosin compared to hydroxyzine and placebo. Improvement in sleep was associated with an amelioration of their PTSD symptoms. Conclusion: Both prazosin and hydroxyzine can be used to treat psychopharmacological sleep disorders and nightmares in patients suffering from PTSD, also leading to reductions in PTSD symptoms.


1 July 2013 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
MHMohammad Haghighi
Mohammad Haghighi
ISIraj Salehi
Iraj Salehi
PEParichehr Erfani
Parichehr Erfani
LJLeila Jahangard
Leila Jahangard
HBHafez Bajoghli
Hafez Bajoghli
Serge BrandSerge Brand
Serge Brand